Pàgina inicial > Resultats de la cerca: Targeted Oncology
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Dipòsit Digital de Documents de la UAB 3 registres trobats  La cerca s'ha fet en 0.00 segons. 
1.
11 p, 832.5 KB Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer : Data from the Prostate Cancer Registry / Bjartell, Anders (Lund University. Department of Translational Medicine, Medical Faculty) ; Lumen, Nicolaas (Universitair Ziekenhuis Gent) ; Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Paiss, Thomas (Urologie team Ulm, Ulm, Germany) ; Gomez-Veiga, Francisco (Instituto de Investigación Biomédica de Salamanca) ; Birtle, Alison (Royal Preston Hospital) ; Kramer, Gero (Medical University of Vienna. Department of Urology) ; Kalinka, Ewa (Polish Mother's Memorial Hospital, Research Institute. Clinic of Oncology) ; Spaëth, Dominique (Centre d'Oncologie de Gentilly, Nancy, France) ; Feyerabend, Susan (Studienpraxis Urologie, Nürtingen, Germany) ; Matveev, Vsevolod (N.N. Blokhin National Cancer Research Center) ; Lefresne, Florence (Janssen Pharmaceutica N.V.. EMEA Oncology) ; Lukac, Martin (Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V) ; Wapenaar, Robert (Janssen-Cilag B.V., Breda, The Netherlands) ; Costa, Luis (Universidade de Lisboa. Oncology Division, Faculdade de Medicina, Hospital de Santa Maria, Instituto de Medicina Molecular) ; Chowdhury, Simon (Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute) ; Universitat Autònoma de Barcelona
Despite standard-of-care androgen-deprivation therapy and an increasing number of treatment options, the mortality rate for prostate cancer remains high. Progress to metastatic castration-resistant prostate cancer (mCRPC) necessitates additional treatments. [...]
2021 - 10.1007/s11523-021-00807-4
Targeted Oncology, Vol. 16 (april 2021) , p. 357-367  
Registre complet - Creative Commons
2.
15 p, 623.6 KB Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer : The Prostate Cancer Registry / Chowdhury, Simon (Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute) ; Bjartell, Anders (Skåne University Hospital (Suècia)) ; Lumen, Nicolaas (Universitair Ziekenhuis Gent) ; Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Paiss, Thomas (Urologie Team Ulm, Ulm, Germany) ; Gomez-Veiga, Francisco (Instituto de Investigación Biomédica de Salamanca) ; Birtle, Alison (Royal Preston Hospital) ; Kramer, Gero (Medical University of Vienna. Department of Urology) ; Kalinka, Ewa (Polish Mother's Memorial Hospital-Research Institute. Clinic of Oncology) ; Spaëth, Dominique (Centre d'Oncologie de Gentilly, Nancy, France) ; Feyerabend, Susan (Studienpraxis Urologie, Nürtingen, Germany) ; Matveev, Vsevolod (N.N. Blokhin National Cancer Research Center) ; Lefresne, Florence (EMEA Oncology, Janssen Pharmaceutica N.V., Beerse, Belgium) ; Lukac, Martin (Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V) ; Wapenaar, Robert (Janssen-Cilag B.V., Breda, the Netherlands) ; Costa, Luis (Universidade de Lisboa. Oncology Division, Hospital de Santa Maria, Instituto de Medicina Molecular, Faculdade de Medicina)
Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients who are under-represented in clinical trials. [...]
2020 - 10.1007/s11523-020-00720-2
Targeted Oncology, Vol. 15 (june 2020) , p. 301-315  
Registre complet - Creative Commons
3.
11 p, 927.9 KB A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer / Wainberg, Zev A. (David Geffen School of Medicina, UCLA (USA)) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Soares, Heloisa P. (Moffitt Cancer Center (USA)) ; Braña, Irene (Princess Margaret Cancer Centre (Canada)) ; Britten, Carolyn D. (Medical University of South Carolina (USA)) ; Del Conte, Gianluca (IRCCS Ospedale San Raffaele(Italy)) ; Ezeh, Patrick (Pfizer Oncology (USA)) ; Houk, Brett (Pfizer Oncology (USA)) ; Kern, Kenneth A. (Pfizer Oncology (USA)) ; Leong, Stephen (University of Colorado (USA)) ; Pathan, Nuzhat (Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121 USA) ; Pierce, Kristen J. (Pfizer Oncology (USA)) ; Siu, Lillian L. (Princess Margaret Cancer Centre (Canada)) ; Vermette, Jennifer (Pfizer Oncology (USA)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors. [...]
2017 - 10.1007/s11523-017-0530-5
Targeted Oncology, Vol. 12, Issue 6 (December 2017) , p. 775-785  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem